Effects of acidic oligosaccharide sugar chain on amyloid oligomer-induced impairment of synaptic plasticity in rats.

Abstract

Soluble amyloid-β protein (Aβ) oligomers have been recognized to be early and key intermediates in Alzheimer's disease-related synaptic dysfunction. In this study, using in vitro electrophysiology, we investigated interactions of the acidic oligosaccharide sugar chain (AOSC), a marine-derived acidic oligosaccharide, with oligomeric Aβ. We found that the inhibition of long-term potentiation (LTP) induced by Aβ oligomers can be dose dependently reversed by the application of AOSC, whereas AOSC alone did not alter normal LTP induction. Interestingly, treatment with Aβ monomers with or without AOSC did not affect LTP induction. Additionally, when fresh-made Aβ was co-incubated with AOSC before in vitro testing, there was no impairment of LTP induction. The results from Western blots demonstrated that AOSC prevent the aggregation of Aβ oligomers. These findings indicate that AOSC may reverse Aβ oligomer-mediated cytotoxicity by directly disrupting the amyloid oligomer aggregation, and this action is concentration dependent. Thus, we propose that AOSC might be a potential therapeutic drug for Alzheimer's disease due to its protection against oligomeric Aβ-induced dysfunction of synaptic plasticity.

• Authors: Lan Chang, Fushun Li, Xiaowei Chen, Shujun Xu, Chuang Wang, Hongzhuan Chen, Qinwen Wang
• Journal: Metabolic brain disease (Metab Brain Dis) Vol. 29 Issue 3 Pg. 683-90 (Sep 2014) ISSN: 1573-7365 [Electronic] United States
• PMID: 24723110 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Amyloid beta-Peptides
• Mannans
• Peptide Fragments
• acidic oligosaccharide sugar chain, Echlonia Kurome Okam

Topics

• Amyloid beta-Peptides (pharmacology)
• Animals
• Hippocampus (drug effects, physiology)
• Long-Term Potentiation (drug effects, physiology)
• Male
• Mannans (pharmacology)
• Peptide Fragments (pharmacology)
• Rats